Stock Insights
Sign up for our newsletter
Stay Informed with TAMIM Market and Stock Insights
At TAMIM, we’re dedicated to empowering investors with knowledge to effectively manage their retirement futures. Our Market and Stock Insights cover various segments to keep you updated on the latest trends, strategies, and news affecting your investments. Explore our wealth of insights across different categories to stay ahead in the evolving landscape of investments.
Subscribe to our Weekly Stock Insights
This week we look to conclude the series with some insights into two more pharma companies that we believe could make for an interesting addition to investor portfolios. Both are potentially high growth and arguably further up the risk curve (if one is to define it by... This week we will be visiting a stock in our Global Mobility portfolio that is poised to benefit from the themes of electrification and autonomy. While these thematics are well known and are well covered, most investors look to only a few select stocks to benefit from... This week we continue on to the final in the pharma series by looking at specific companies that we feel are worth at least a review by investors. As elucidated last time, the categories that offer the most lucrative long-term opportunities are Oncology, Diabetes and... This week we continue to look at the global pharmaceutical industry. More specifically, this week we will be looking to identify some of the trends and segments which may produce some more lucrative opportunities. Before we begin, a quick recap of the main points... Over the past few weeks we have been covering stocks we believe are poised to benefit from the ongoing reopening of Australia and New Zealand. This week we will be writing about a small cap payments company that should be a huge beneficiary of this reopening... This week we begin a new series centred around the global pharmaceutical sector with a particular eye to ascertaining where the opportunities and risks may be. Going back to our broader macro views, in particular around inflation, this sectoral allocation is one that... Robert Swift takes a look at what happened in October in markets. This is an excerpt from Robert's Global High Conviction report for October 2021. Global equity returns were unusually strong in October rising over 4.5% in USD terms and essentially flat in AUD as the... This week we visit our second category within the mobility thematic, that is autonomy. A topic that is arguably more important than the general electrification of transport, we arrive at three key considerations for those wishing to take advantage of the thematic.... This week we revisit the property market, specifically the potential/future for commercial office space. We are in the process of offering our most recent buy in the Adelaide CBD and throughout the process we have consistently received questions around the prudence...
Pharma: Investing in the Pipeline, Not the Products
1 Stock to Benefit from Electrification, Autonomy & Sharing
Pharma: DexCom & BMS | Can giants grow?
Pharma: Diabetes, Cancer & Cardiovascular/Respiratory
Smart Money Is On This Payments Company
Pharma: Broad Strokes, Covid-19 & Revisiting Pfizer
Global Market Update | October 2021
Mobility Part 3: 3 Key Considerations for Investing in Autonomous Vehicles
Property: The Upside to Office Space Dislocations
This week we look to conclude the series with some insights into two more pharma companies that we believe could make for an interesting addition to investor portfolios. Both are potentially high growth and arguably further up the risk curve (if one is to define it by... This week we will be visiting a stock in our Global Mobility portfolio that is poised to benefit from the themes of electrification and autonomy. While these thematics are well known and are well covered, most investors look to only a few select stocks to benefit from... This week we continue on to the final in the pharma series by looking at specific companies that we feel are worth at least a review by investors. As elucidated last time, the categories that offer the most lucrative long-term opportunities are Oncology, Diabetes and... This week we continue to look at the global pharmaceutical industry. More specifically, this week we will be looking to identify some of the trends and segments which may produce some more lucrative opportunities. Before we begin, a quick recap of the main points... Over the past few weeks we have been covering stocks we believe are poised to benefit from the ongoing reopening of Australia and New Zealand. This week we will be writing about a small cap payments company that should be a huge beneficiary of this reopening... This week we begin a new series centred around the global pharmaceutical sector with a particular eye to ascertaining where the opportunities and risks may be. Going back to our broader macro views, in particular around inflation, this sectoral allocation is one that... Robert Swift takes a look at what happened in October in markets. This is an excerpt from Robert's Global High Conviction report for October 2021. Global equity returns were unusually strong in October rising over 4.5% in USD terms and essentially flat in AUD as the... This week we visit our second category within the mobility thematic, that is autonomy. A topic that is arguably more important than the general electrification of transport, we arrive at three key considerations for those wishing to take advantage of the thematic.... This week we revisit the property market, specifically the potential/future for commercial office space. We are in the process of offering our most recent buy in the Adelaide CBD and throughout the process we have consistently received questions around the prudence...
Pharma: Investing in the Pipeline, Not the Products
1 Stock to Benefit from Electrification, Autonomy & Sharing
Pharma: DexCom & BMS | Can giants grow?
Pharma: Diabetes, Cancer & Cardiovascular/Respiratory
Smart Money Is On This Payments Company
Pharma: Broad Strokes, Covid-19 & Revisiting Pfizer
Global Market Update | October 2021
Mobility Part 3: 3 Key Considerations for Investing in Autonomous Vehicles
Property: The Upside to Office Space Dislocations
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.No Results Found
About TAMIM Asset Management
TAMIM Asset Management is a boutique investment firm that provides a variety of investment solutions tailored to our clients’ needs, with a commitment to safeguarding their wealth. At TAMIM we delivering expert solutions across equities, property & credit
Stay Informed with TAMIM Stock Insights
TAMIM Asset Management provides market and stock insights for general information to help you understand our investment approach. Any financial information we provide is not advice, has not considered your personal situation, and may not be suitable for you.